Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
2026-02-25 15:48:39 ET
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
According to its SEC filing dated February 17, 2026, BVF fully liquidated its stake in Protagonist Therapeutics (NASDAQ:PTGX) , selling 2,560,916 shares. The quarter-end position value decreased by $170.12 million.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging peptide technology to address unmet needs in hematology and immunology. The company’s strategic partnerships and robust pipeline position it as a key innovator within the biotechnology sector. Its focus on advancing mid-stage clinical assets supports long-term growth potential and competitive differentiation.
NASDAQ: PTGX
PTGX Trading
1.66% G/L:
$96.65 Last:
202,192 Volume:
$96.02 Open:
